Clinical Trials Logo

Healthy Volunteers clinical trials

View clinical trials related to Healthy Volunteers.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 10

NCT ID: NCT01446120 Not yet recruiting - Healthy Volunteers Clinical Trials

Insulin Loaded Orally Dissolved Films (Insulin-ODF)

Start date: n/a
Phase: Phase 1
Study type: Interventional

This study is assessing the pharmacokinetics efficacy and of Insulin loaded Orally Dissolved Films (insulin-ODF) treatment. The Insulin-ODF is attached to the inner tissue of the chick (buccal) , Releasing the insulin to the circulation, while the film is dissolved.. Primary endpoint: 1. The Cmax (Maximum Concentration of insulin in mg). 2. Tmax (the time to Cmax in minutes) 3. AUC (Area Under the Curve) of blood insulin levels during six hours of the trial. Secondary endpoints: 1. The glucose and C-peptide levels during six hours of the trial. (mg) 2. The safety of the treatment in a descriptive manner by recording all adverse events in the study population. Methods Seven healthy volunteers will be randomly assigned to one of the following groups: A. Insulin-ODF following treatment group; Or B. commercial NPH Insulin treatment. The study is designed a crossover, in which each group is treated 3-7 days of washout. The volunteer subjects will arrive to the clinic after eight hours fasting. Each subject will be examined by a physician, evaluating the elegibilities to the trial (i.e. inclusion and exclusion criteria). An I.V catheter will be administrated assessing the Glucose, Insulin and C-peptide levels, ten minutes and five minutes before injecting the NPH Insulin or the Insulin-ODF. Blood Insulin and glucose levels will be evaluated at baseline, and after the following time points: 15,30,60,90,120,150,180,210,240,270,300,330,360 minutes. C-peptide levels will be evaluated at baseline and after the following time points: 60,120,240, 360 minutes.

NCT ID: NCT01383330 Not yet recruiting - Healthy Volunteers Clinical Trials

A Clinical Trial to Evaluate Pharmacokinetics of Daewon DW-ES(A) 625mg/5ml, Daewon DW-ES(B) 625mg/5ml and Megace 800mg/20ml in Healthy Male Volunteers Under Fed Condition

Start date: July 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate pharmacokinetics of Daewon DW-ES(A) 625mg/5ml, Daewon DW-ES(B) 625mg/5ml and Megace 800mg/20ml in healthy male volunteers under fed condition.